StockData
Prime Medicine, Inc. logo

Prime Medicine, Inc. (PRME) stock

PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.84−0.35 (-8.35%)

Close on Nov 17, 2026Market cap $696.49MP/E –Yield –

Prime Medicine cash

Cash and short-term investments held at the end of each period.

Prime Medicine's cash was $95.10M at Jun 30, 2026. For fiscal 2025 it was $177.70M, down 6.7% from the year before. The highest annual figure on record is $293.90M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$177.70M-6.7%
FY2024Dec 31, 2024$190.40M+56.5%
FY2023Dec 31, 2023$121.70M-58.6%
FY2022Dec 31, 2022$293.90M+10.2%
FY2021Dec 31, 2021$266.78M+621.5%
FY2020Dec 31, 2020$36.98M+327.6%
FY2019Dec 31, 2019$8.65M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$95.10M-6.6%
Q1 FY2026Mar 31, 2026$135.50M-6.1%
Q4 FY2025Dec 31, 2025$177.70M-6.7%
Q3 FY2025Sep 30, 2025$213.30M+21.5%
Q2 FY2025Jun 30, 2025$101.80M-37.5%
Q1 FY2025Mar 31, 2025$144.30M-31.5%
Q4 FY2024Dec 31, 2024$190.40M+56.5%
Q3 FY2024Sep 30, 2024$175.50M+6.2%
Q2 FY2024Jun 30, 2024$162.90M-21.5%
Q1 FY2024Mar 31, 2024$210.70M-15.6%
Q4 FY2023Dec 31, 2023$121.70M-58.6%
Q3 FY2023Sep 30, 2023$165.30M+12.7%
Q2 FY2023Jun 30, 2023$207.60M+125.1%
Q1 FY2023Mar 31, 2023$249.50M+51.9%
Q4 FY2022Dec 31, 2022$293.90M+10.2%
Q3 FY2022Sep 30, 2022$146.70M-26.9%
Q2 FY2022Jun 30, 2022$92.24M+149.5%
Q1 FY2022Mar 31, 2022$164.25M+1799.5%
Q4 FY2021Dec 31, 2021$266.78M–
Q3 FY2021Sep 30, 2021$200.66M–
Q4 FY2020Dec 31, 2020$36.98M–
Q4 FY2019Dec 31, 2019$8.65M–

More Prime Medicine figures

See a number that looks wrong?